Physician profile
Gwyn E King
NPI 1659569382
$60,782.78
in general payments reported to CMS, 2019-2025
30 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $15K · 2021: $21K · 2022: $9,354 · 2023: $506 · 2024: $538 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $57,247.86 | 2019-2025 | Nemluvio |
| Abbvie INC. | $967.70 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $480.06 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $335.84 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $295.31 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $293.61 | 2021-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $271.00 | 2019-2025 | |
| Allergan, INC. | $127.97 | 2019-2021 | |
| Genentech USA, INC. | $80.94 | 2019-2020 | |
| Dermavant Sciences, INC. | $65.12 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $64.55 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $62.44 | 2023-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $46.04 | 2025 | Acthar |
| Dusa Pharmaceuticals, INC. | $45.03 | 2019 | |
| Incyte Corporation | $43.40 | 2025 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $42.14 | 2020-2021 | |
| Organon LLC | $39.17 | 2025 | Vtama |
| Leo Pharma INC. | $28.14 | 2025 | Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $27.93 | 2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $24.92 | 2023 | Ycanth |
| Amgen INC. | $24.48 | 2023 | Otezla |
| Arcutis Biotherapeutics, INC. | $24.06 | 2023 | |
| Biofrontera INC. | $22.11 | 2019 | |
| Pfizer INC. | $20.90 | 2025 | |
| Celgene Corporation | $19.36 | 2019 | |
| Krystal Biotech INC | $18.79 | 2025 | Vyjuvek |
| Prugen, INC. Pharmaceuticals | $18.36 | 2019 | |
| Kyowa Kirin, INC. | $18.24 | 2025 | |
| Genzyme Corporation | $15.49 | 2021 | |
| Mylan Pharmaceuticals INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwyn King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.